DAWN Stock Overview
A clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Day One Biopharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.58 |
| 52 Week High | US$18.07 |
| 52 Week Low | US$11.94 |
| Beta | -1.52 |
| 1 Month Change | -9.69% |
| 3 Month Change | -10.14% |
| 1 Year Change | -13.84% |
| 3 Year Change | -27.99% |
| 5 Year Change | n/a |
| Change since IPO | -51.41% |
Recent News & Updates
Recent updates
Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically
Nov 04
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
Jul 12Day One Biopharmaceuticals: Still Uncertainty After FDA Approval
Jul 07Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Apr 24We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 18Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Feb 01We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Dec 04We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Jun 19We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 08Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation
Nov 22Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead
Sep 04Day One Biopharmaceuticals GAAP EPS of -$0.60
Aug 04Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Intrinsic Value Is Potentially 52% Above Its Share Price
Jun 18Day One Biopharmaceuticals: Early Pediatric Brain Cancer Data Makes Tentative Buy Case
Jun 15We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Apr 29An Intrinsic Calculation For Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Suggests It's 42% Undervalued
Jan 14Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Dec 10Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Aug 27Day One Biopharma draws bullish calls as quiet period ends
Jun 21Shareholder Returns
| DAWN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.9% | 0.7% | 0.6% |
| 1Y | -13.8% | -3.4% | 23.7% |
Return vs Industry: DAWN underperformed the US Biotechs industry which returned -3.4% over the past year.
Return vs Market: DAWN underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| DAWN volatility | |
|---|---|
| DAWN Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DAWN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DAWN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 174 | Jeremy Bender | dayonebio.com |
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2.
Day One Biopharmaceuticals, Inc. Fundamentals Summary
| DAWN fundamental statistics | |
|---|---|
| Market cap | US$1.30b |
| Earnings (TTM) | -US$84.29m |
| Revenue (TTM) | US$101.95m |
12.4x
P/S Ratio-15.1x
P/E RatioIs DAWN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DAWN income statement (TTM) | |
|---|---|
| Revenue | US$101.95m |
| Cost of Revenue | US$2.30m |
| Gross Profit | US$99.66m |
| Other Expenses | US$183.95m |
| Earnings | -US$84.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 97.75% |
| Net Profit Margin | -82.68% |
| Debt/Equity Ratio | 0% |
How did DAWN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 22:47 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Day One Biopharmaceuticals, Inc. is covered by 13 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Naureen Quibria | Capital One Securities, Inc. |
| Andrea Newkirk | Goldman Sachs |